After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of NewAmsterdam Pharma Company NV is $2.78B. A total of 0.49 million shares were traded on the day, compared to an average of 875.28K shares.
In the most recent transaction, Kastelein Johannes Jacob Piete sold 50,000 shares of NAMS for 25.14 per share on Aug 22 ’25. After the transaction, the Chief Scientific Officer now owns 69,302 company shares. In a previous transaction on Aug 21 ’25, Kastelein Johannes Jacob Piete sold 50,000 shares at 24.29 per share. NAMS shares that Chief Scientific Officer owns now total 119,302.
Among the insiders who bought shares, Kastelein Johannes Jacob Piete acquired of 100,000 shares on Aug 21 ’25 at a per-share price of $25.00. In another insider transaction, Topper James N bought 471 shares at $23.98 per share on Aug 11 ’25. Company shares held by the Director now total 3,026,604.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, NAMS has a high of $27.29 and a low of $14.06.
As of this writing, NAMS has an earnings estimate of -$0.36 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.44. The company reported an EPS of -$0.16 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. NAMS’s latest balance sheet shows that the firm has $60.11M in Cash & Short Term Investments as of fiscal 2021. There were $185.68k in debt and $11.19M in liabilities at the time. Its Book Value Per Share was $6.92, while its Total Shareholder’s Equity was $56.37M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NAMS is Buy with a score of 4.57.
